靶向壳聚糖新型纳米药物体外抗胰腺癌细胞的实验研究
投稿时间:2016-10-13  修订日期:2016-10-31  点此下载全文
引用本文:俞海波,陈海川,王哲近,麻忠武,肖竣,贺亚东.靶向壳聚糖新型纳米药物体外抗胰腺癌细胞的实验研究[J].医学研究杂志,2017,46(6):84-87
DOI: 10.11969/j.issn.1673-548X.2017.06.022
摘要点击次数: 980
全文下载次数: 689
作者单位E-mail
俞海波 325000 温州市中心医院肝胆外科 zjuboby@163.com 
陈海川 325000 温州市中心医院肝胆外科  
王哲近 325000 温州市中心医院肝胆外科  
麻忠武 325000 温州市中心医院肝胆外科  
肖竣 325000 温州市中心医院肝胆外科  
贺亚东 325000 温州市中心医院肝胆外科  
基金项目:浙江省医药卫生科技计划项目(2013KYB248);浙江省温州市医药卫生科研项目(2016A02);浙江省温州市公益性科技计划项目(Y20160527)
中文摘要:目的 合成靶向表皮生长因子受体(EGFR)壳聚糖吉西他滨纳米粒,研究其在体外胰腺癌细胞的靶向性及对细胞增殖的影响。方法 采用壳聚糖制备EGFR-吉西他滨-壳聚糖纳米粒(G-GC-Dox)、吉西他滨-壳聚糖纳米粒(GC-Dox)。在体外实验研究中将药物作用于EGFR+胰腺癌细胞系SW1990细胞,研究胰腺癌细胞体外摄取实验,并采用四甲基偶氮唑蓝法(MTT)法观察该体系对胰腺癌SWl990细胞生长增殖的影响。结果 EGFR-吉西他滨-壳聚糖纳米粒组体外SW1990胰腺癌细胞平均摄取纳米药物的量明显强于同一时间点吉西他滨-壳聚糖纳米粒组平均摄取纳米药物的量。G-GC-Dox组处理12、24、48h后细胞存活率(43.14%±2.51%、31.21%±2.37%、18.26%±2.75%)对比GC-Dox组(64.22%±3.11%、45.43%±3.04%、35.23%±3.15%)对肿瘤细胞具有更好的抑制作用(P<0.05)。结论 本实验成功研制了靶向EGFR壳聚糖吉西他滨纳米粒,并证实了该纳米粒能提高药物在体外胰腺癌细胞的靶向性,同时对胰腺癌SW1990细胞增殖具有明显抑制作用,可能为将来靶向治疗胰腺癌提供新的研究思路。
中文关键词:胰腺肿瘤  增殖  吉西他滨  壳聚糖
 
Experimental Study on Anti-pancreatic Cancer Cells Treated with Chitosan Targeted Nano Drugs
Abstract:Objective Synthesis of epidermal growth factor receptor (EGFR) gemcitabine chitosan nanoparticles. To study the targeting effect of pancreatic cancer cells in vitro and cell proliferation. Methods EGFR-gemcitabine-chitosan nanoparticles(G-GC-Dox) and gemcitabine-chitosan nanoparticles(GC-Dox) were prepared by emulsion polymerization method. In vitro immunofluorescence was used to study the intake test of EGFR+ carried SW1990 cells in G-GC-Dox and GC-Dox. Their ability to inhibit the proliferation of SW1990 cell lines by methylthiazolyl tetrazolium (MTT) were also tested. Results Compared to GC-Dox,G-GC-Dox had a better drug concentration in SW1990 cell. The survival rates of SW1990 cells were(43.14%±2.51%,31.21%±2.37%,18.26%±2.75%) when treated with G-GC-Dox after 12h,24h,48h, the survival rate of SW1990 cells were (64.22%±3.11%,45.43%±3.04%,35.23%±3.15%)when treated with GC-Dox.The differences had statistical significance(P<0.05). Conclusion G-GC-Dox was successfully developed. The nanoparticles could improve drug targeting of pancreatic cancer cells in vitro and enhance the antitumor of pancreatic cancer. In future, it May provide a new train of thought for the treatment of pancreatic cancer.
keywords:Pancreatic neoplasms  Proliferation  Gemcitabine  Chitosan
查看全文  查看/发表评论  下载PDF阅读器

京公网安备 11010502037822号